Physiomics Plc (PYC) - Total Liabilities

Latest as of December 2025: GBX165.00K GBX ≈ $20.08 USD

Based on the latest financial reports, Physiomics Plc (PYC) has total liabilities worth GBX165.00K GBX (≈ $20.08 USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Physiomics Plc (PYC) equity growth momentum to track the company's year-over-year net asset growth rate.

Physiomics Plc - Total Liabilities Trend (2001–2025)

This chart illustrates how Physiomics Plc's total liabilities have evolved over time, based on quarterly financial data. See Physiomics Plc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.

Physiomics Plc Competitors by Total Liabilities

The table below lists competitors of Physiomics Plc ranked by their total liabilities.

Company Country Total Liabilities
Alina Holdings PLC
LSE:ALNA
UK GBX787.39K
Mobile Max-M
TA:MBMX
Israel ILA2.40 Million
Gaming Technologies Inc. Common Stock
NASDAQ:GMGT
USA $5.17 Million
Catenai PLC
LSE:CTAI
UK GBX253.69K
Hsin Yung Chien Co Ltd
TW:2114
Taiwan NT$597.24 Million
Botswana Diamonds plc
LSE:BOD
UK GBX1.17 Million
AMUR MINERALS (A7L.SG)
STU:A7L
Germany €425.00K
IQ-AI Ltd
LSE:IQAI
UK GBX627.14K

Liability Composition Analysis (2001–2025)

This chart breaks down Physiomics Plc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see PYC stock market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 3.30 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.42 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.30 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Physiomics Plc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Physiomics Plc (2001–2025)

The table below shows the annual total liabilities of Physiomics Plc from 2001 to 2025.

Year Total Liabilities Change
2025-06-30 GBX199.85K
≈ $24.32
+42.68%
2024-06-30 GBX140.08K
≈ $17.04
-1.82%
2023-06-30 GBX142.67K
≈ $17.36
+1.47%
2022-06-30 GBX140.61K
≈ $17.11
-10.76%
2021-06-30 GBX157.57K
≈ $19.17
+19.81%
2020-06-30 GBX131.52K
≈ $16.00
+52.27%
2019-06-30 GBX86.37K
≈ $10.51
-32.63%
2018-06-30 GBX128.21K
≈ $15.60
+47.50%
2017-06-30 GBX86.92K
≈ $10.58
-12.34%
2016-06-30 GBX99.16K
≈ $12.06
+86.22%
2015-06-30 GBX53.25K
≈ $6.48
-50.56%
2014-06-30 GBX107.71K
≈ $13.10
-13.59%
2013-06-30 GBX124.64K
≈ $15.17
+18.11%
2012-06-30 GBX105.53K
≈ $12.84
-5.78%
2011-06-30 GBX112.00K
≈ $13.63
-17.04%
2010-06-30 GBX135.00K
≈ $16.43
-62.50%
2009-06-30 GBX360.00K
≈ $43.80
-23.08%
2008-06-30 GBX468.00K
≈ $56.94
+129.41%
2007-06-30 GBX204.00K
≈ $24.82
-3.77%
2006-06-30 GBX212.00K
≈ $25.79
+85.96%
2005-06-30 GBX114.00K
≈ $13.87
-74.50%
2004-06-30 GBX447.00K
≈ $54.39
+114.90%
2003-06-30 GBX208.00K
≈ $25.31
+2211.11%
2001-06-30 GBX9.00K
≈ $1.10
--

About Physiomics Plc

LSE:PYC UK Biotechnology
Market Cap
$26.47K
GBX217.54 Million GBX
Market Cap Rank
#31578 Global
#1247 in UK
Share Price
GBX0.48
Change (1 day)
+0.00%
52-Week Range
GBX0.27 - GBX0.70
All Time High
GBX17.13
About

Physiomics Plc provides consulting services to pharmaceutical companies in the areas of outsourced quantitative pharmacology and computational biology in the United Kingdom, the United States, and the European Union Switzerland. The company offers modeling, simulation, and data analysis services covering various ranges of oncology research and development using its proprietary Virtual Tumour pred… Read more